Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1 Genotype-Guided Dosing of Irinotecan + FOLFIRI + Cetuximab in mCRC
NCT02573220Phase 1Withdrawn
- Sponsor
- University of Chicago
- Start
- Jun 2015
- Primary completion
- Aug 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Jun 2015; status: withdrawn.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02573220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573220.